| Prev Close | 53.94 |
| Open | 53.70 |
| Day Low/High | 52.97 / 53.75 |
| 52 Wk Low/High | 31.25 / 58.46 |
| Volume | 440.93K |
| Avg Volume | 766.30K |
| Exchange | NASDAQ |
| Shares Outstanding | 86.75M |
| Market Cap | 4.70B |
| EPS | -1.10 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Neurocrine Biosciences to Present at the Baird 2016 Healthcare Conference
Live Audio Webcast will be on September 7, 2016
Neurocrine Announces Initiation Of A Long-Term Phase II Clinical Study Of VMAT2 Inhibitor Valbenazine In Tourette Syndrome
Six Month Open Label Safety and Tolerability Study of Valbenazine
Short Interest In Neurocrine Biosciences Jumps 14%
The most recent short interest data has been released for the 07/15/2016 settlement date, which shows a 606,250 share increase in total short interest for Neurocrine Biosciences, Inc. , to 4,930,434, an increase of 14.02% since 06/30/2016.
Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2016 Results
Conference Call and Webcast Scheduled For Wednesday, August 3, 2016
Bearish Bets: Biotech, Energy and Other Stocks that Look Good to Short
NBIX, ZPIN, VLP, NWLI and INFO were all recently downgraded by TheStreet's Quant Ratings.
Biogen Should Either a Buyer or a Seller Be
The company sans CEO Scangos needs to do some type of deal in the coming months.
Ratings Changes Today
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ESNT, HBHC, HMY, IILG, MYCC, NEWM, PRTY, TOT, VTTI Downgrades: NBIX Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Short Interest In Neurocrine Biosciences Decreases By 30%
The most recent short interest data has been released for the 06/30/2016 settlement date, which shows a 1,864,374 share decrease in total short interest for Neurocrine Biosciences, Inc. , to 4,324,184, a decrease of 30.13% since 06/15/2016.
Neurocrine Biosciences To Present At The Jefferies 2016 Healthcare Conference
Live Audio Webcast will be on June 8, 2016
Neurocrine Biosciences (NBIX) Strong On High Relative Volume Today
Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a strong on high relative volume candidate
Insider Trading Alert - NBIX, FRGI And LBAI Traded By Insiders
Stocks with insider trader activity include NBIX, FRGI and LBAI
Xenoport's Cost-Cutting Tactics Lead to Buyout With Hefty Premium
The biotechnology company, which makes alcoholism drug Horizant, was acquired by privately held Arbor Pharmaceuticals for $467 million in cash, a price lower than at least one analyst expected.
Strong On High Volume: Neurocrine Biosciences (NBIX)
Trade-Ideas LLC identified Neurocrine Biosciences (NBIX) as a strong on high relative volume candidate
Short Interest Moves 11% Higher For NBIX
The most recent short interest data has been released for the 04/29/2016 settlement date, which shows a 692,785 share increase in total short interest for Neurocrine Biosciences, Inc. , to 6,943,712, an increase of 11.08% since 04/15/2016.
Neurocrine Biosciences To Present At The Bank Of America Merrill Lynch 2016 Health Care Conference
Live Audio Webcast will be on May 12, 2016
Neurocrine Biosciences Announces Additional Valbenazine (NBI-98854) Data To Be Presented At The American Psychiatric Association's 2016 Annual Meeting In Atlanta
Four Abstracts Submitted and Accepted for the May 2016 APA Annual Meeting
Neurocrine Biosciences Announces Conference Call And Webcast To Report First Quarter 2016 Results
Conference Call and Webcast Scheduled For Thursday, May 5, 2016
Neurocrine Biosciences To Present At The Deutsche Bank 41st Annual Health Care Conference
Live Audio Webcast will be on May 4, 2016
'Mad Money' Lightning Round: I'm Taking Starbucks Over Bojangles
Cramer prefers Southwest over JetBlue and is waiting on Boeing.
Jim Cramer's 'Mad Money' Recap: Uncle Sam, Back Off Business!
Cramer says the political rhetoric against Big Business is heading down a dangerous path.
Neurocrine Biosciences (NBIX) Stock Gets ‘Outperform’ Rating at BMO Capital
Neurocrine Biosciences (NBIX) stock was started with an ‘outperform’ rating and $57 price target at BMO Capital Markets.
Neurocrine Biosciences To Present At The Barclays Global Healthcare Conference
Live Audio Webcast will be on March 15, 2016
Neurocrine Biosciences To Present At The Cowen And Company 36th Annual Health Care Conference
Live Audio Webcast will be on March 9, 2016
Neurocrine Biosciences Announces The Acceptance Of Three Scientific Abstracts For Valbenazine (NBI-98854) At The 68th Annual Meeting Of The American Academy Of Neurology In Vancouver April 2016
Kinect 3 Clinical Study Data Accepted for Plenary Session
Neurocrine Biosciences Announces Conference Call And Webcast To Report Fourth Quarter And Year-End 2015 Results
Conference Call and Webcast Scheduled For Thursday, February 11, 2016
